Events Archives - Page 192 of 287

TuesdayMar 20, 2018 9:00 am

Disrupting Business: Blockchain Technology Offers Solutions across the Board

NetworkNewsWire Editorial Coverage: Renowned British theoretical physicist Stephen Hawking, before passing away March 14, 2018, recently offered this observation (http://nnw.fm/07THl) about artificial intelligence: “The rise of AI could be the worst or the best thing that has happened for humanity.” For those companies immersed in developing blockchain technology, the famous scientist’s words underscore the responsibility tech companies shoulder as the integration between this technological trend and the Internet of Things (IoT) opens up promising new frontiers (http://nnw.fm/4cwMz). As a strong proponent of blockchain technology for the finance market’s logistics supply chain integrity and high-risk sectors such as legalized cannabis, Global…

WednesdayMar 14, 2018 9:00 am

Enterprise Blockchain Solutions Emerging in Cross-Industry Sectors

NetworkNewsWire Editorial Coverage: It’s difficult to imagine childhood without a set of building blocks, be it Tinkertoys, Legos, or the tried-and-true backyard stick structures. Regardless of the construction method, the drive to solve problems and build something useful never really goes away, especially when it comes to business. In fact, it’s the anchoring thought behind the blockchain revolution made famous by bitcoin and other cryptocurrencies. Blockchain technology, described as a distributed database or ledger that maintains a continuous list of transactions or records, has the potential to disrupt any public or private sector. Companies actively pursuing and building on the…

WednesdayMar 14, 2018 9:00 am

Preventive Medical Solutions Integrate with Major Cannabis Providers for Innovative Drug Delivery

NetworkNewsWire Editorial Coverage: As the legal cannabis market continues to grow, new deals are creating opportunities for a range of companies and an influx of investments. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) has teamed up with research institutions in Australia and gained a government permit to import cannabis for development of its drug delivery system. Cannabis for this project will be supplied by Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB), a company experiencing significant production growth, including a deal for a new joint venture in Denmark. ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) (ABCCF Profile) is expanding…

TuesdayMar 13, 2018 2:49 pm

IEG Holdings Corp. (IEGH) Revenues Pegged to Quadruple by 2020

IEG Holdings services vast underbanked market in U.S. Company enjoys 80 percent repeat customer business ACF Equity Research projects that company revenues will quadruple from 2017 estimates by 2020 In a January 2018 report, ACF Equity Research projected that IEG Holdings Corp. (OTCQB: IEGH) revenues will essentially quadruple over the next couple years and the company will maintain positive EBITDA (http://nnw.fm/i9LkJ). Serving the large underbanked population in the United States, IEG Holdings provides unsecured, five-year consumer loans of $5,000 and $10,000 under the brand name ‘Mr. Amazing Loans’ through its website (www.MrAmazingLoans.com). The company is licensed and/or holds certificates of…

TuesdayMar 13, 2018 2:00 pm

IRIDEX Corp. (NASDAQ: IRIX) Starts Presentation at 30th Annual ROTH Conference

IRIDEX (NASDAQ: IRIX) develops, manufactures and markets innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The company maintains a deep commitment to the success of its customers, with comprehensive technical, clinical, and service support programs. The company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of…

TuesdayMar 13, 2018 12:00 pm

Enphase Energy, Inc. (NASDAQ: ENPH) Starts Presentation at 30th Annual ROTH Conference

Enphase Energy (NASDAQ: ENPH) is a global energy technology company that delivers simple, innovative and reliable energy management solutions that advance the worldwide potential of renewable energy. The company sells its microinverter systems primarily to distributors, as well as directly to large installers through original equipment manufacturers and strategic partners. Enphase has shipped approximately 16 million microinverters, and approximately 700,000 Enphase residential and commercial systems have been deployed in more than 100 countries. For more information, visit the company’s website at www.enphase.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a…

TuesdayMar 13, 2018 12:00 pm

GP Strategies Corp. (NYSE: GPX) Starts Presentation at 30th Annual ROTH Conference

GP Strategies (NYSE: GPX) is a global performance improvement solutions provider of sales and technical training, eLearning solutions, management consulting and engineering services. GP Strategies’ solutions improve the success of organizations by delivering innovative and superior training, consulting and business improvement services, customized to meet the specific needs of its clients. Clients include Fortune 500 companies, manufacturing, process and energy industries, and other commercial and government customers. For more information, visit the company’s website at www.gpstrategies.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to…

TuesdayMar 13, 2018 11:00 am

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Starts Presentation at 30th Annual ROTH Conference

Ritter Pharmaceuticals (NASDAQ: RTTR) is engaged in the development of novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. RP-G28, the company’s lead product, has the potential to become the very first FDA-approved lactose intolerance treatment, addressing a condition that affects millions of individuals throughout the world. This product has been studied in phase 2 trials and is currently in phase 3 clinical development. Ritter Pharmaceuticals is additionally exploring the functionality and discovering the therapeutic potential of gut microbiome changes on treating and/or preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic and liver disease. For more information, visit…

MondayMar 12, 2018 5:00 pm

Blue Bird Corp. (NASDAQ: BLBD) Starts Presentation at 30th Annual ROTH Conference

Blue Bird (NASDAQ: BLBD) is an independent designer and manufacturer of school buses, with more than 550,000 buses sold since its formation in 1927 and approximately 180,000 buses in operation today. Blue Bird focuses on the design, engineering, manufacture and sale of school buses and related parts. The company is the only manufacturer of chassis and body production specifically designed for school bus applications, and offers alternative fuel applications with its propane-powered and compressed natural gas-powered school buses. Blue Bird manufactures school buses at two facilities in Fort Valley, Georgia. Its Micro Bird joint venture operates a manufacturing facility in…

MondayMar 12, 2018 3:30 pm

Eyenovia, Inc. (NASDAQ: EYEN) Starts Presentation at 30th Annual ROTH Conference

Eyenovia (NASDAQ: EYEN) is a late-stage biopharmaceutical company engaged in developing a pipeline of ophthalmology products in the United States. The company is building its portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. The company has three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. The company is advancing its two lead assets for glaucoma and mydriasis into phase 3 clinical programs and preparing registration studies for a third OTC product for dry eye. For more information, visit the company’s website at www.eyenoviabio.com. About NetworkNewsWire…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Category: Events